Continuous Glucose Monitoring–Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-standing Type 2 Diabetes Switched From a Daily Basal Insulin to Once-Weekly Insulin Icodec: Post Hoc Analysis of ONWARDS 2 and ONWARDS 4
Diabetes Care2024Vol. 47(4), pp. 729–738
Citations Over TimeTop 10% of 2024 papers
Harpreet S. Bajaj, Björg Ásbjörnsdóttir, Lisbeth Carstensen, Christian Laugesen, Chantal Mathieu, Athena Philis‐Tsimikas, Tadej Battelino
Abstract
In insulin-experienced participants with long-standing type 2 diabetes, CGM-based TIR, TAR, and CGM-derived hypoglycemia duration (<3.9 mmol/L) were comparable for icodec and once-daily basal insulin analogs during all time periods. TBR remained within recommended targets.
Related Papers
- → Accuracy of the GlucoWatch G2 Biographer and the Continuous Glucose Monitoring System During Hypoglycemia(2004)112 cited
- → Associations Between the Time in Hypoglycemia and Hypoglycemia Awareness Status in Type 1 Diabetes Patients Using Continuous Glucose Monitoring Systems(2020)35 cited
- → Continuous Glucose Monitor Shows Potential for Early Hypoglycemia Detection in Hospitalized Patients(2009)27 cited
- → Impact in real-world of intermittent-scanned continuous glucose monitoring with alarms on hypoglycemia and its recognition in type 1 diabetes(2024)2 cited
- → Continuous Glucose Monitoring Device for the Prevention of Severe Hypoglycemia(2008)